during multiple passages are currently unavailable, it has not been feasible to use conventional gene transfer approaches that rely on transfection, stable integration, and selection of a given gene in clonal myocardial cell populations. As a result, much of the recent work in the field of cardiac molecular biology has resorted to either transient expression studies or the generation of transgenic mice that express a given gene in a cardiac-or muscle-specific manner. Unfortunately, transfection of primary neonatal rat myocardial cells is a relatively low-efficiency procedure for gene transfer (0.1-3%), and it is difficult to precisely identify the cells that are expressing the foreign gene, which eliminates the possibility of using sensitive single-cell assays. In addition, the successful transfection and expression of gene constructs in cultured adult differentiated myocardial cells has not been reported, which restricts the potential application of this approach to study signaling mechanisms in adult myocytes. Similarly, the generation of transgenic mice is laborious and expensive and thus does not represent an optimal primary approach for screening a large number of gene constructs. The site of integration, copy number, and potential lethality of the transgene are also important limitations to this experimental approach. Accordingly, there appears to be a clear need to develop and characterize alternative means to manipulate gene expression in living cardiac muscle cells.
In other cell types, the application of microinjection approaches to introduce defined signaling molecules and expression vectors into single cells has led to an improved understanding of the pathways that activate cell growth and proliferation. [18] [19] [20] [21] [22] In the cardiac cell context, it has been possible to deliver various calcium dyes by microinjection and to monitor short-term physiological responses. 23 Although a similar approach would be valuable in the study of signaling mechanisms that regulate cardiac growth and development, it has proved difficult to inject neonatal myocardial cells without the concomitant loss of long-term viability of the successfully injected myocytes. In fact, there have been no reports of the successful microinjection of these cells with the efficient maintenance of long-term cell viability. Although the detailed basis for this difficulty still remains elusive, it is suggested that micropuncture can lead to defects in the sarcolemmal membrane that are associated with the influx of extracellular calcium, hypercontraction, and sarcolemmal bleb formation and are characteristic of myocardial cell injury observed during ischemia and ATP depletion.2425
Through a systematic and extensive analysis of the potential experimental variables, the present study reports the efficient microinjection of living neonatal cardiac muscle cells with a 20-30-fold increase in cell viability over conventional methods. The improvement is based on the selection of an appropriate plating substratum, the identification of optimal injection parameters, and the addition of agents to minimize myocardial cell damage Neonatal ventricular myocytes were cultured as previously described.8'16 Twenty-four hours after plating, the media were aspirated, and cells were rinsed once and then incubated in fresh media. Thirty-eight to 42 hours after the initial plating, the cells were incubated in fresh medium containing 20 mM 2,3-butanedione monoxime (BDM) for at least 1 hour before injection and were maintained in this medium throughout the microinjection procedure and for 4-6 hours after injection, unless indicated otherwise. Subsequently, the cells were rinsed and incubated in the appropriate BDM-free medium until harvest.
Preparation of Injectants
The injectant buffer was 100 mM potassium chloride/5 mM potassium phosphate, pH 7.4, unless indicated otherwise. Immunopurified marker mouse or rabbit IgG (Sigma) was resuspended and dialyzed against several volumes of injectant buffer, aliquoted, and stored at -80°C. Immediately before use, the IgG samples were centrifuged at 14,000 rpm for 10 minutes in a microfuge to pellet the particulate material. The supernatants were microinjected into cells at a concentration of 2-4 mg IgG/ml. DNA samples were precipitated, pelleted, washed with 70% ethanol, resuspended in injectant buffer, and stored at 4°C. Before use, DNA samples were to pellet the particulate material and injected at concentrations ranging from 0.2 to 1.0 mg/ml.
Injection Parameters and Protocol
In these studies, the Eppendorf ECET microinjector 5242 system, the ECET micromanipulator 5170 system, the ECET Femtotips, and a Zeiss Axiovert inverted microscope were used for microinjection. Cytoplasmic injections of ventricular myocytes were performed with a 0.5-second injection time and 30-50 hPa injection pressure. Cytoplasmic and nuclear injections of Rat 2 fibroblasts were both performed with a 0.5-second injection time and injection pressures of 100-120 or 30-40 hPa, respectively. In all the above-mentioned microinjection applications, both the axial and the Z (depth) limit options on the microinjection apparatus were used so that the microinjection needle enters the cell at an angle of 45°. To perform nuclear microinjections of the cardiac myocytes, the axial option on the microinjection apparatus was switched off so that the needle enters vertically into the cell nucleus, with a 0.3-second injection time and an injection pressure of 70 hPa. Not all microinjection attempts are successful. In this study, a successful microinjection attempt indicates a successful delivery of the injectant into the cell. This is judged visually by observing the flow of the injectant into the cells in the form of a transient wave that moves within the cell and is accompanied by a transient swelling of the microinjected cell. However, not all successfully injected cells survive this manipulation. Thus, the efficiency of the technique was calculated as the total number of successfully injected cells that survived and maintained long-term viability after microinjection. (Efficiency=100xnumber of viable successfully injected cells/total number of successfully injected cells.) In our hands, cytoplasmic microinjection of marker IgG into Rat 2 fibroblasts resulted in a high level of efficiency, reaching 100%, with long-term viability extending to 48 hours after injection (Table 1) . In contrast, repeated attempts to perform cytoplasmic injections of marker IgG into neonatal rat ventricular myocytes using the same parameters and conditions resulted in a low efficiency that did not exceed 1 % because of the low viability of these cells after microinjection. In most cases, the microinjected cells displayed hypercontracture shortly after microinjection, followed by blebbing of the sarcolemmal membrane and immecentrifuged for 10 minutes in a microfuge at 14,000 rpm diate lifting off the surface of the culture dishes. Neonatal rat ventricular myocytes were cultured as described under "Methods," and 1 hour before microinjection they were incubated in fresh maintenance medium (MM) containing antibiotics, serum, and 20 mM BDM. Cytoplasmic injection of immunopurified rabbit or mouse IgG (2 mg/ml) was performed at injection pressure of 40-50 hPa and an injection time of 0.5 seconds. Cells were maintained in the same injection media for [4] [5] [6] proteins.9> i34 In the present study, an increase in cell profile and the organization of MLC-2 into sarcomeric units were used as appropriate criteria to assess the ability of the microinjected myocytes to initiate a normal hypertrophic response after treatment with the a-adrenergic agonist phenylephrine. Myocardial cells were injected with 2 mg/ml of marker IgG in the presence of BDM, maintained in the same injection media for 4 hours after injection, and then subsequently incubated in serum-free maintenance medium in the presence or absence of 100 ,M phenylephrine. As illustrated in Figure 1 , clusters of viable, microinjected cardiac myocytes were detected 48 hours after microinjection with the marker IgG. These cells were surrounded by a background of nonmicroinjected cells that displayed negative staining for the IgG, i.e., negative Texas red staining. The ax-adrenergic stimulation of both the microinjected and the nonmicroinjected cells resulted in a marked increase in cell size and an increase in the assembly of MLC-2 into organized contractile units, as assessed by indirect immunocytofluorescence staining with trpE-MLC-2 antisera.8
Results

Loss of Cell Viability After Microinjection of
Thus, the microinjection of a nonspecific marker IgG does not interrupt a-adrenergic activation of the hypertrophic response in living cardiac muscle cells. Through the microinjection of antibodies that neutralize specific signaling molecules, it should now be possible to directly assess the role of specific gene products in the activation of a complex, hypertrophic response. The direct microinjection of purified recombinant proteins that activate or inhibit cardiac muscle cell growth and hypertrophy Figure 2A assayed by immunocytofluorescence with rabbit anti-luciferase immune sera and fluorescein-conjugated goat anti-rabbit IgG to detect luciferase expression. Neonatal rat ventricular myocytes were cultured and cytoplasmically microinjected with a combination of mouse IgG (2 mg/ml) and either pRSVLAS'
(panels C and D) orpANF (-638) LAS (panels E, F, G, and H) (1 mg/ml) as explained for Table 2 and under "Methods." Forty-eight hours later, the cells were assayed by indirect dual immunocytofluorescence using biotinylated sheep anti-mouse IgG and streptavidin-Texas red to detect surviving microinjected cells (panels C, E, and G) and with rabbit anti-luciferase immune serum and fluorescein-conjugated goat anti-rabbit IgG to detect luciferase expression (panels D, F, and H). Panels C, E, and G represent the same groups of cells as in panels D, F, and H, respectively (magnifications: panel A, x220; panel B, x140; panels C, D, E, and F, x 1, 650; panels G and H, x 970). pON249 microinjection studies, no assessment of the total percentage of cell viability is presented, because the immunocytofluorescence assays to detect marker IgG are not compatible with the histochemical analysis of the f3-galactosidase activity. Thus, efficiency=lOOx number of cells expressing f-galactosidase/total number of successfully injected cells. It is important to note that, in this study, absolutely no f3-galactosidase activity was detected in fibroblasts or ventricular myocytes that were not microinjected with the f-galactosidase expression vector pON249, as measured by histochemical analysis using X-Gal. In addition, such cells transfected with pON249 did express positive fB-galactosidase activity in the histochemical assays, whereas nontransfected cells did not (data not shown). These observations preclude the problem of leakiness in P-galactosidase activity that is observed in other systems.30 Thus, the fields of nonmicroinjected cells that display negative staining for fl-galactosidase and that surround the groups of blue positively stained microinjected cells (Figures 2A and  2B ) represent appropriate negative controls and indicate the specificity of the assay. Because cytoplasmic microinjection of expression vectors into cells proved to be effective in achieving their expression in cardiac myocytes and not in fibroblasts, our data suggest fundamental differences between these two types of cells, one of which may be the levels of cytoplasmic nuclease activity.
A series of studies was conducted to determine whether genes under the control of cardiac specific promoters would also be expressed after cytoplasmic microinjection of ventricular myocytes. The cardiac promotor-reporter gene constructs that were available at the time contained luciferase as the reporter gene.
Accordingly, neonatal rat myocardial cells were cytoplasmically microinjected with a combination of the marker mouse IgG and the cardiac promotor-luciferase reporter fusion gene construct, ANF-luciferase [pANF(-638)LA5'], which was shown to be activated after stimulation of the neonatal ventricular myocytes with a hypertrophic stimulus (phenylephrine)9 ( Figures  3E-3H ). In control experiments, an RSV promotorluciferase reporter fusion gene construct, pRSVLA5', was coinjected with the marker mouse IgG instead of the ANF-luciferase construct ( Figures 3C and 3D 
Ventricular Myocytes
As mentioned earlier, because of the diminutive size of the ventricular myocyte nuclei under certain experimental conditions, we initially experimented with cytoplasmic injections of expression vectors into cardiac myocytes. As our experience with the technique widened, however, it became important to adapt it to the nuclear microinjection of cardiac cells, because such an approach has been proved from previous studies21 in other cell systems to be the most efficient in obtaining detectable expression of exogenous genes. To that end, and using the CMV-,8-galactosidase expression vector pON249, we have succeeded in modifying the microinjection technique, as described under "Methods," to be able to perform nuclear microinjections of the ventricular myocytes. As displayed in Figure 4 , the nuclear injection of pON249 allowed the expression of the ,-galactosidase reporter in clusters of microinjected ventricular myocytes at a 30% efficiency (efficiency= 100xnum-ber of cells expressing 13-galactosidase/total number of successfully injected cells). These 
